A proud moment captured at the Start4Health Acceleration Lab awards ceremony, where the team secured second place in Pfizer’s innovative healthcare startup competition.
Deloitte’s Startup Accelerator
AimaLabs is excited to announce that following our pitch presentation at the Demo Day, we have been selected to join Deloitte’s Startup Accelerator program. This achievement marks a significant milestone in our journey, and we look forward to leveraging this opportunity to accelerate our growth and innovation in deep tech solutions. We are grateful for this recognition and eager to collaborate with Deloitte’s extensive network of experts and mentors.
Won Beyond Tomorrow 2025 Pitch Competition
We are pleased to announce that AimaLab has been awarded second place at the Beyond Tomorrow 2025 Pitch Competition. Competing against numerous innovative startups, our deep tech solution was recognized by the judging panel for its innovative approach and market potential. This achievement at such a prestigious event validates our vision and technological development. We thank the Beyond Tomorrow organization for this recognition and are motivated to continue advancing our innovative solutions.
We are thrilled to announce that AimaLab is participating in NVIDIA’s Inception Program, joining a select group of cutting-edge AI startups. This collaboration with NVIDIA’s premier startup platform provides us access to cutting-edge technology resources, technical expertise, and a global network of AI innovators. Being part of NVIDIA’s Inception program reinforces our commitment to pushing the boundaries of AI innovation and accelerates our development of advanced deep tech solutions.
Automated Recognition of Spherocytes Through Artificial Intelligence: A Promising Approach
V. Vlacha, A. Perivolaropoulos, P. Perivolaropoulou, D. Tikhomirov
We are pleased to announce that AimaLabs presented research findings at the 10th Greek Pediatric Hematology Conference in November 2024. This presentation demonstrates our commitment to advancing medical diagnostics through cutting-edge artificial intelligence solutions and reinforces our collaboration with the medical community in developing practical applications for clinical practice.
Panathenea 2025
AimaLabs made its mark at the groundbreaking Panathenea 2025, Athens’ most anticipated technology gathering! We were thrilled to be part of this dynamic event that brought together the brightest minds in tech, right in the cradle of innovation – Athens, Greece.
At Panathenaea 2025, we expanded our network, shared insights about our latest developments, and engaged in meaningful discussions about the future of technology. The event proved to be an excellent platform for fostering new partnerships and exploring potential collaborations.
AimaLabs Receives Honorary Award at University of Ioannina’s Innovation Competition
We are delighted to announce that AimaLabs has been honored with an award at the recent startup competition hosted by the University of Ioannina’s Innovation & Entrepreneurship Center and Mantis Beyond Innovation.
The competition, which took place last weekend, brought together innovative startups and entrepreneurs, showcasing cutting-edge solutions across various sectors. Our team presented our healthcare technology solutions, demonstrating our commitment to transforming laboratory and hospital operations.
This recognition from the University of Ioannina and mantis Beyond Innovation validates our mission and strengthens our dedication to revolutionizing healthcare technology across Greece and beyond.
We extend our sincere gratitude to:
• The University of Ioannina’s Innovation & Entrepreneurship Center (Μονάδα Καινοτομίας και Επιχειρηματικότητας)
• Mantis Beyond Innovation
• The distinguished panel of judges
Together, we’re creating innovative solutions that will shape tomorrow’s healthcare landscape.
AimaLabs Honored with Award at Ioannina University’s Innovation Challenge
AimaLabs was honored with an award at the recent innovation competition organized by the University of Ioannina’s Innovation & Entrepreneurship Center in collaboration with Mantis Beyond Innovation. We presented our healthcare technology solutions, demonstrating our commitment to transforming laboratory and hospital operations.
AimaLabs Wins Third Place at StartSmart SEE Accelerator Demo Day during MIT Universal AI Summit 7/2025
We are proud to announce that AimaLabs has been awarded Third Place at the StartSmart SEE Accelerator Demo Day during the MIT Universal AI Summit 2025 in Athens. This recognition highlights our team’s commitment to developing innovative artificial intelligence solutions that address real-world healthcare challenges.
At AimaLabs, we specialize in AI-powered peripheral blood cell recognition technology, revolutionizing diagnostic capabilities in hematology. Our cutting-edge approach aims to enhance accuracy and efficiency in blood analysis, supporting healthcare professionals in delivering better patient outcomes.
Competing alongside exceptional startups from across Southeast Europe, we had the opportunity to showcase our vision and connect with industry leaders who share our passion for technological advancement in healthcare.
The StartSmart SEE Accelerator program has been an invaluable journey of growth, learning, and refinement. We are grateful for the guidance, resources, and network that helped us strengthen our approach and broaden our horizons.
We extend our sincere gratitude to the judges for their thoughtful evaluation and feedback, as well as to the entire StartSmart SEE team for creating such an impactful program. Special thanks to Dr Vasilis Papakonstantinou and Dr. Gerasimos Spyridakis for their leadership and dedication to fostering innovation in our region.
We also thank The People’s Trust for their sponsorship and our mentor Dionysis Spiliopoulos for his invaluable guidance.
This achievement belongs to our entire dedicated team: Christos Maniatis, Daniel Tikhomirov, Angelos Perivolariopoulos, and Persephoni Perivolalopoulou and Vasiliki Vlacha. Each team member brings unique expertise and experience, creating a strong and complementary unit that combines knowledge from different domains of technology and medicine.
As we continue our mission to innovate and create impact, this recognition energizes us for the exciting challenges ahead. The future of AI in healthcare is collaborative, and we are honored to be part of this dynamic ecosystem.
AimaLabs Selected to Present at Prestigious European ESIL ePitch Event
AimaLabs will showcase its revolutionary AI-powered platform for hematology to a curated audience of Europe’s leading investors and business angels.
AimaLabs, a leader in applying artificial intelligence to hematology diagnostics, is honored to announce its selection to present at the upcoming European ESIL ePitch session on September 15, 2025, at 16:30 CET.
Hosted by European ESIL, the ePitch is a premier event designed to connect the most promising deep-tech companies with an influential network of investors, business angels, and strategic ecosystem partners. The event’s impact is amplified through a valuable collaboration with three of Europe’s key investment players: Business Angels Europe, Bpifrance | EuroQuity, and META Group.
This selection serves as a major validation of AimaLabs’ mission to bring groundbreaking innovation to the field of hematology. At the session, the company will showcase its proprietary AI-powered platform, which automates and enhances the identification of peripheral blood cells. This technology is poised to increase diagnostic accuracy, streamline laboratory workflows, and ultimately improve patient outcomes.
All interested parties, including investors and potential partners, are invited to attend the virtual session.
Event Details:
- Event: European ESIL ePitch Session
- Date: September 15, 2025
- Time: 16:30 CET
- Registration: The official link for registration will be posted here as soon as it becomes available. Please check back for updates.
AimaLabs Launches Key Clinical Study with Aigio General Hospital to Validate AI-Powered Blood Cell Analysis
We are thrilled to announce that AimaLabs has officially launched a pivotal clinical study for the validation of our AI-powered diagnostic platform in collaboration with the Aigio General Hospital in Greece.
This crucial study, encompassing 300 patients from various departments over a 6-9 month period, is designed to rigorously evaluate the accuracy and efficiency of our technology against the current gold standard of manual microscopy.
We are honored to be working under the expert guidance of Dr. Panagiota Xaplanteri, Director of the Diagnostic Laboratory at Aigio Hospital. Her leadership and deep expertise in clinical diagnostics are invaluable to ensuring the scientific rigor and success of this study.
This collaboration marks a major milestone in our mission to close the diagnostic gap for blood disorders. The data generated will be foundational for our regulatory submissions and will bring us one step closer to making fast, accurate, and accessible diagnostics a reality for every patient.
Stay tuned for updates on our progress!
DECEMBER 2025
AimaLabs Ranked Among Top 10 Biotech Startups in Greece by F6S
We are honored to announce that AimaLabs has been recognized by F6S, ranking #9 in the “Top 13 Biotech Startups in Greece” for December 2025.
While accolades are appreciated, we view this recognition primarily as a validation of our core mission: leveraging advanced Artificial Intelligence to revolutionize the diagnosis and management of anemia and blood disorders.
With 1.5 billion people globally affected by these conditions, the need for scalable, high-precision solutions has never been greater. This ranking belongs to our dedicated team of engineers and medical experts who are bridging the gap between deep tech and patient care.
We extend our gratitude to the F6S community for the spotlight, and to our mentors who continue to guide our growth within Greece’s thriving biotech ecosystem.
AIMA Labs 